Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mirxes Closes $50 Million Round for miRNA Tests; Will IPO in Hong Kong

publication date: Jul 28, 2023

Mirxes Holding, a Singapore RNA diagnostic company, closed a Series D funding round that raised $50 million. The company also filed for a Hong Kong IPO. Mirxes was founded to develop its ID3EAL reverse transcription quantitative polymerase chain reaction (RT-qPCR) platform for detecting microRNAs and other non-coding RNAs. This technology is the basis for Mirxes’ GASTROClear gastric cancer early detection test, which is already available, and serves as the basis for the company’s multi-cancer early detection clinical pipeline. Mirxes will use the funds to advance its portfolio of early detection blood tests for cancer and preventive healthcare solutions. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital